OR WAIT 15 SECS
Takeda will acquire ARIAD Pharmaceuticals for approximately $5.2 billion.
On Jan. 9, 2017, Takeda announced plans to acquire ARIAD Pharmaceuticals for $24 per share in cash, or approximately $5.2 billion. The acquisition of ARIAD brings two targeted therapies that will expand Takeda’s existing oncology portfolio. The transaction is expected to close by the end of February 2017.
Under the terms of the agreement, Takeda will acquire birgatinib and Iclusig from ARIAD. Brigatinib is an investigational drug product for the treatment of a genetically-defined subpopulation of non-small cell lung cancer. Iclusig is a treatment for chronic myeloid leukemia and a subset of acute lymphoblastic leukemia. These two targeted therapies will position Takeda for long-term growth in oncology, the company said in a press announcement.
ARIAD provided calendar year 2016 revenue guidance for Iclusig of $170-180 million, and Takeda expects significant long-term revenue potential from the two lead assets. Takeda will leverage ARIAD’s R&D capabilities and platform, and largely absorb its R&D costs within Takeda's existing R&D budget.